46 items

Perimenopause Symptom & Hormone Therapy Tracker

A structured daily and weekly tracking system for women navigating perimenopause — covering vasomotor symptoms, cycle irregularity, sleep, mood, cognition, genitourinary health, HRT response monitoring, and specialist appointment preparation. For more background and examples, see the guidance below; for built-in tools and options, use the quick tools guide.

Author

Checklistify Editorial Team

Last Updated

Checklist Items

0 done•46 left•9 of 10 sections collapsed

Log each hot flash: time of day, severity (1–5), duration in minutes, and any identifiable trigger

Hot flashes are the most diagnostically informative perimenopause symptom — their frequency, severity, and timing pattern directly informs treatment selection and dosing. Common triggers worth documenting include alcohol, caffeine, spicy food, stress, warm environments, and specific clothing fabrics. Trigger identification enables behavioral management alongside or prior to pharmaceutical treatment, and a consistent trigger pattern may reduce daily frequency without any pharmacological intervention.

Log each night sweat episode: approximate time, severity (1–5), and whether it required changing clothes or bedding

Night sweats that require clothing or bedding changes are clinically more significant than those causing mild awakening. The frequency and severity of night sweats is a primary measure of HRT effectiveness — logging them consistently before and after HRT initiation gives you and your clinician objective evidence of treatment response. A daily count of 8 dropping to 3 over six weeks of HRT is meaningful clinical evidence of dose adequacy that verbal recall cannot reliably replicate.

Log total hot flash and night sweat count for the day

Daily totals tracked across weeks reveal patterns invisible in single-day data: time-of-month clustering, weekday versus weekend differences that suggest stress-related contribution, and post-treatment reduction trajectory. These aggregate patterns inform whether dose adjustment or behavioral modification is the more productive next step.

Note any palpitations or heart racing associated with hot flashes or occurring independently

Cardiac palpitations are a documented perimenopause symptom driven by estrogen fluctuation's effect on cardiac conduction. However, palpitations that are sustained, occur at rest without an associated hot flash, or are accompanied by chest pain or shortness of breath require same-day cardiology evaluation and should not be attributed to perimenopause without first ruling out cardiac causes.

Log the first day of each menstrual period (Day 1 = first day of full flow) and total duration of flow

Perimenopause is defined in part by cycle irregularity — cycles that were predictable begin to lengthen, shorten, or skip. The only way to document this diagnostic pattern is consistent first-day logging. A record showing cycle lengths of 28, 31, 45, 22, and 62 days tells a clinical story that 'my periods have been irregular' cannot. Irregular data is still valuable data — incomplete logging is more useful than no logging.

Log flow heaviness each day of period: light, moderate, heavy, or very heavy (soaking a pad or tampon in under 2 hours)

Perimenopausal heavy menstrual bleeding — particularly flooding, passing large clots, or soaking through protection in under 2 hours — requires clinical evaluation. It can indicate fibroids, endometrial hyperplasia, or coagulopathy rather than simple hormonal fluctuation. Document and report any episodes of very heavy flow rather than normalizing them as a perimenopause variant without clinical assessment.

Log any mid-cycle spotting or intermenstrual bleeding with date and estimated cycle day

Postmenopausal bleeding — any bleeding occurring 12 months after the last period — requires immediate gynecological evaluation to rule out endometrial pathology. Mid-cycle spotting during active perimenopause is common but should still be documented: a pattern of persistent intermenstrual bleeding warrants endometrial assessment regardless of assumed hormonal cause.

Note your current cycle length relative to your personal historical baseline

Your personal baseline — not a population average — is the reference point for identifying perimenopausal cycle change. A woman whose historical cycle was 35 days experiencing 50-day cycles has a different change magnitude than a woman whose baseline was 28 days. Record your pre-perimenopause average cycle length at the start of tracking so all subsequent data is contextualized against it.

Log any ovulation signs if tracking: cervical mucus changes, OPK results, and mid-cycle pelvic discomfort

Ovulation continues intermittently throughout perimenopause, which means pregnancy remains possible until 12 consecutive months without a menstrual period — the clinical definition of menopause. Women who are not trying to conceive should not assume they are infertile during the perimenopause transition. Contraception guidance should be an explicit part of your perimenopause clinical conversation.

List all current or recently discontinued hormonal contraceptives with start and stop dates

Hormonal contraceptives — particularly combined oral contraceptives and the hormonal IUS — can mask perimenopausal cycle changes and suppress vasomotor symptoms, making it difficult to assess true perimenopause status and severity while using them. If you have recently stopped hormonal contraception, note the date: many perimenopausal symptoms emerge or intensify in the months following discontinuation, and this context is critical for accurate clinical assessment.

#10

Log total sleep hours and sleep quality rating (1–5) each morning before caffeine or screens

Sleep disruption in perimenopause is driven by multiple mechanisms: night sweats causing awakening, progesterone decline reducing sleep-promoting neurosteroid activity, and direct estrogen effects on sleep architecture. Tracking sleep quality alongside night sweat frequency allows you and your clinician to distinguish thermoregulatory sleep disruption — which responds to HRT — from primary insomnia, which may require a separate behavioral or pharmacological intervention.

#11

Log time to fall asleep, number of awakenings, and whether you felt rested upon waking

Difficulty initiating sleep, difficulty maintaining sleep, and early morning awakening have different underlying mechanisms and different treatment implications. Documenting the specific pattern — rather than summarizing it as 'poor sleep' — provides your clinician with the information needed to target treatment accurately and avoid a one-size-fits-all sleep intervention.

#12

Note any restless legs symptoms overnight: frequency, severity, and whether movement provides relief

Restless legs syndrome worsens significantly during perimenopause and menopause, likely driven by estrogen and dopamine interactions. If you experience uncomfortable leg sensations that worsen at rest and improve with movement, document frequency and severity — RLS is frequently undertreated in the perimenopause context and responds to specific interventions that differ from general sleep hygiene recommendations.

#13

Log any sleep apnea symptoms: snoring reported by a partner, witnessed breathing pauses, or morning headaches

The incidence of obstructive sleep apnea increases significantly in women during the menopause transition, driven by upper airway changes and loss of progesterone's protective effect on airway muscle tone. New or worsening snoring, witnessed apneas, or persistent morning headaches in a perimenopausal woman warrant a sleep study referral. Sleep apnea is significantly underdiagnosed in women and represents a major independent cardiovascular risk factor.

#14

Rate mood today on a 1–5 scale: 1 = significantly depressed or anxious, 3 = your personal baseline, 5 = well

Perimenopause is associated with a 2–4 fold increase in the risk of a major depressive episode — particularly in women with a prior history of PMS, PMDD, or postpartum depression. Estrogen affects serotonin, dopamine, and GABA systems, which is the biological basis for this vulnerability. Daily mood ratings correlated with cycle phase and vasomotor symptom severity help distinguish hormonally-driven mood change from primary depression — a distinction with significant treatment implications that verbal description in an appointment cannot reliably convey.

#15

Note any anxiety episodes: severity (1–5), duration, presence of panic features, and whether a situational trigger was present

New-onset anxiety in perimenopause — particularly anxiety that arrives without a situational trigger — is often driven by estrogen fluctuation and may respond to HRT in ways that situational anxiety does not. Document whether anxiety episodes cluster around specific cycle phases, follow hot flash events, or occur in the early morning hours when estradiol levels are at their daily low point. This pattern data is clinically actionable in a way that 'I've been feeling anxious' is not.

#16

Log any irritability or emotional dysregulation: severity and whether the reaction felt proportionate to the trigger

A hallmark perimenopause mood symptom is an irritability or emotional response that feels disproportionate to the situation — recognizable to the woman herself as 'not like me.' This symptom is frequently not raised in clinical settings because women minimize it or attribute it to stress. Documenting its frequency and context provides your clinician with evidence that emotional dysregulation is a symptom requiring assessment, not a personality shift requiring acceptance.

#17

Log any cognitive symptoms: brain fog episodes, word retrieval difficulty, memory lapses, or impaired concentration

Cognitive symptoms during perimenopause — particularly verbal memory and processing speed changes — are well-documented and mechanistically linked to estrogen's role in hippocampal function. These symptoms are highly distressing, frequently mistaken by patients for early dementia, and rarely proactively addressed by clinicians. Document frequency and functional impact — they are treatable and should be an explicit part of your clinical conversation.

#18

Note any loss of motivation, depersonalization, or difficulty with tasks previously managed without effort

Reduced executive function and motivation during perimenopause is distinct from clinical depression but can precede it. A consistent pattern of feeling overwhelmed by previously routine tasks, combined with low mood ratings and disrupted sleep, should prompt a clinical mental health screening — not an expectation of self-management or a default prescription for an antidepressant without hormonal assessment.

#19

Log any vaginal dryness, discomfort during intercourse, or vulvar irritation: severity (1–5) and frequency this week

Genitourinary syndrome of menopause affects up to 60% of postmenopausal women but begins during perimenopause. Unlike vasomotor symptoms, which often improve over time after menopause, GSM is progressive and does not resolve without treatment. It responds well to local estrogen therapy, which carries a different — and generally more favorable — risk profile than systemic HRT. Document and raise it: it is undertreated primarily because women do not initiate the conversation.

#20

Log urinary symptoms this week: urgency, increased frequency, leaking with urgency or physical activity, or recurrent UTI-like symptoms

Urinary symptoms in perimenopause are driven by estrogen's role in urethral and bladder tissue health. These symptoms are frequently normalized as 'part of aging' and not raised with clinicians. Local vaginal estrogen significantly reduces recurrent UTI rates and improves urinary urgency in postmenopausal women — document and request evaluation rather than managing with over-the-counter urinary analgesics indefinitely.

#21

Note any changes in libido: decreased, absent, or in some cases transiently increased

Libido changes in perimenopause are multifactorial: declining testosterone and estrogen, GSM pain during intercourse, mood and sleep disruption, medication effects, and relationship context all contribute. Documenting the change and its relationship to other symptoms helps clinicians distinguish hormonally-driven libido change from psychosocial drivers — each requires a different intervention strategy.

#22

Log morning blood pressure (take two readings 2 minutes apart and record both): systolic/diastolic and resting heart rate

Estrogen is cardioprotective, and its decline during perimenopause is associated with measurable cardiovascular risk escalation. Morning home blood pressure monitoring at a consistent time — seated, before caffeine, after 5 minutes of rest — establishes your personal baseline trend and flags elevations that require clinical management independent of HRT decisions. Cardiovascular disease is the leading cause of death in postmenopausal women: this is not optional monitoring.

#23

Log weight weekly: same time of day, same scale, without clothing

Perimenopause is associated with changes in fat distribution — increased visceral adiposity can occur even at a stable total weight — as well as declining insulin sensitivity and metabolic rate changes. Consistent weekly weight tracking at a fixed time establishes the actual rate of change, which is often slower than perceived, and documents whether specific dietary or activity changes are producing a measurable effect.

#24

Log physical activity: type (resistance, aerobic, flexibility), duration, and perceived intensity

Resistance training during perimenopause has evidence for preserving muscle mass — which declines with estrogen loss — improving insulin sensitivity, supporting bone density, and reducing vasomotor symptom severity. Aerobic exercise independently reduces cardiovascular risk. Tracking both types alongside your symptom data frequently reveals a direct relationship between exercise frequency and symptom severity that is motivating in a way that general health advice is not.

#25

Note any new joint pain, stiffness, or tendon discomfort — particularly if it appeared or worsened during perimenopause

Musculoskeletal pain — joint pain, tendon pain, and widespread stiffness — is one of the most common and least recognized perimenopause symptoms, driven by estrogen's role in joint and connective tissue health. Women who develop widespread joint pain during perimenopause are frequently worked up for rheumatological conditions without estrogen deficiency being considered as a primary driver. Document the onset and its temporal relationship to other perimenopausal symptoms.

#26

Record your complete HRT regimen: estrogen type, progestogen type if applicable, dose, and delivery route

HRT regimens vary significantly in their risk and benefit profiles based on type, route, and dose. Transdermal estradiol carries lower venous thromboembolism and stroke risk than oral estrogen. Body-identical progesterone (micronized progesterone) has a more favorable breast tissue risk profile than synthetic progestins. Document your exact regimen so you can compare it to current evidence-based guidelines and discuss route or type changes if your response is suboptimal or side effects are problematic.

#27

Log HRT start date and complete the MRS (Menopause Rating Scale) on day of initiation to establish your symptom baseline

The Menopause Rating Scale is an 11-item validated symptom score covering somatic, psychological, and urogenital domains. Completing it on the day you begin HRT creates the baseline against which all subsequent scores are compared. Without a documented baseline, HRT effectiveness assessment relies on subjective recall rather than objective measurement — a significant limitation in any treatment requiring dose optimization.

#28

Log each HRT dose application: date, time, application site for transdermal, and any application issues

Transdermal HRT efficacy depends on consistent application to clean, dry skin at appropriate body sites. Patch detachment, application over skin with lotion, or rotation to anatomically incorrect sites all reduce absorption. Log any application issues — variable absorption is a common and frequently underrecognized cause of inconsistent symptom control that is often misattributed to insufficient dose.

#29

Complete the MRS symptom score at weeks 4, 8, and 12 after HRT initiation and compare each to your baseline

Hot flash frequency and sleep improvement typically begin within 2–4 weeks of adequate estrogen dosing. Mood and cognitive improvement may take 8–12 weeks. Genitourinary symptom improvement may take 12 or more weeks. Scoring at each interval identifies which symptom domains are responding and which may require dose adjustment, additional therapy, or a different delivery route.

#30

Log all HRT side effects with onset date and severity: breast tenderness, bloating, irregular spotting, headache, mood changes

Many HRT side effects are dose-dependent and resolve with dose adjustment, regimen change, or route change rather than discontinuation. Breast tenderness is common with oral estrogen and often resolves when switching to transdermal delivery. Irregular spotting in the first 3–6 months of a continuous combined regimen is expected — persistent spotting beyond 6 months requires endometrial evaluation and should be reported promptly rather than tolerated.

#31

Log breakthrough vasomotor symptoms on HRT: time of day, severity, and days elapsed since last dose application

Vasomotor symptoms that return before the next scheduled dose — particularly patch symptoms in the 24–48 hours before a scheduled patch change — indicate insufficient dose or absorption and constitute a direct clinical signal for regimen review. This specific dosing-interval symptom pattern is actionable data that your clinician can use to make a targeted adjustment.

#32

Document any decision to change, pause, or discontinue HRT: date, clinical reason, and who made the decision

HRT regimen changes are frequently made during acute health events — surgery, new diagnoses, illness — and then continued or not continued without a formal subsequent review. Documenting every regimen change with its clinical rationale creates a medication history that prevents the common situation of a woman being unable to recall what she was taking, at what dose, or why it was changed.

#33

Log DEXA scan results with date: T-score and Z-score at lumbar spine and total hip

Bone density declines most rapidly in the first 5 years after the final menstrual period — the window during which HRT has its greatest protective effect on bone. A baseline DEXA is recommended for women entering perimenopause with risk factors including smoking history, family history of fracture, low BMI, corticosteroid use, or history of an eating disorder. Log T-scores at every DEXA and track the trend across scans rather than reading each result in isolation.

#34

Log calcium and Vitamin D supplementation: dose, timing, and estimated daily calcium from dietary sources

Calcium (1,000–1,200 mg per day from food and supplements combined) and Vitamin D (1,500–2,000 IU per day for most women — confirm with your clinician based on your serum level) support bone density during the perimenopause transition. Log your estimated dietary calcium alongside supplements: combined intake matters, and supplementing above dietary needs increases kidney stone risk without additional bone benefit.

#35

Log annual laboratory results with dates: lipid panel, fasting glucose, TSH, and Vitamin D level

Perimenopause independently worsens lipid profiles — LDL rises, HDL may fall, and triglycerides increase — and reduces insulin sensitivity. Tracking these annually establishes whether metabolic changes require intervention independent of or alongside HRT. Thyroid dysfunction, particularly Hashimoto's thyroiditis, shares multiple symptoms with perimenopause including fatigue, weight changes, mood disturbance, and cognitive fog. Annual TSH testing prevents years of perimenopausal misattribution.

#36

Log mammogram and cervical screening results with dates and recommended return intervals

HRT decisions require current mammography and cervical screening results — screening is not optional if you are considering or continuing HRT. Log your last mammogram result, the recommended return interval, and your cervical screening status. Any recommended follow-up imaging should be completed before initiating or continuing a new HRT regimen.

#37

Document your personal symptom onset timeline: when each major symptom category first appeared and in what sequence

The chronological sequence in which perimenopause symptoms appeared — whether cycle changes preceded vasomotor symptoms, or mood and cognitive symptoms emerged years before any cycle irregularity — is diagnostically informative and often differs from the assumed pattern. A written timeline that covers the past 2–4 years, even approximately, gives your clinician a longitudinal view that a single appointment cannot reconstruct from memory. Note any significant life events or medication changes that coincide with symptom onset.

#38

Print or export your 8–12 week symptom log with daily hot flash counts, sleep ratings, mood ratings, and cycle documentation

An 8-week log showing daily hot flash frequency of 12–15, nightly awakenings with severity 4–5 night sweats, and consistent mood ratings of 2–3 is objective clinical evidence that justifies HRT initiation or dose escalation. The same information presented verbally as 'I've been having a lot of hot flashes and not sleeping well' does not produce the same clinical response — the written log transforms a 20-minute appointment into a targeted treatment planning session.

#39

Bring all MRS scores with dates — your initiation baseline and every subsequent scored interval

MRS scores across multiple time points reveal your symptom trajectory in a way that is immediately actionable. An MRS of 28 at baseline, dropping to 18 at 8 weeks on HRT, and returning to 24 at 16 weeks suggests an initial response followed by dose inadequacy — a specific clinical pattern with a specific solution that is invisible without the longitudinal data.

#40

Prepare a complete current medication and supplement list including all phytoestrogens and herbal products

Herbal supplements commonly used for perimenopause symptoms — black cohosh, red clover, dong quai, St. John's Wort — have drug interactions and in some cases estrogenic activity that affects HRT dosing decisions and safety assessments. Your clinician must know everything you are taking. List all supplements explicitly, including dose and frequency: products marketed as 'natural' are not pharmacologically inert.

#41

Prepare a concise personal and family medical history summary: breast cancer, blood clots, stroke, cardiovascular disease, osteoporosis

HRT risk-benefit assessment is highly individual and depends heavily on personal and family history. A woman with no family history of breast cancer and a strong family history of cardiovascular disease has a different HRT risk-benefit profile than the reverse. Prepare a concise written family history to bring to every menopause consultation — this information may directly change the recommended formulation, route, or dose.

#42

List your top 3 symptoms by quality-of-life impact and state them at the start of the appointment

Perimenopause spans so many symptom domains that 20-minute appointments are frequently dominated by whichever symptom surfaces first, leaving others unaddressed. Open by naming your priorities: 'I want to make sure we cover sleep, mood, and the joint pain — which do you recommend we prioritize today?' This simple framing prevents the most common appointment outcome: leaving with one symptom addressed and three others carried forward to the next visit.

#43

Calculate weekly averages for daily hot flash count, sleep quality rating, and mood rating — note any shifts from the prior week

Week-over-week comparison smooths out day-to-day variability and reveals whether your symptom picture is stable, improving, or worsening. A four-week trend of increasing hot flash frequency on an otherwise stable HRT regimen is a dose signal. A sudden week of worsening mood in an otherwise stable pattern may correlate with a stressful event, a missed dose, or a hormonal fluctuation around cycle phase — context that weekly review makes visible.

#44

Review HRT compliance this week: any missed doses, late applications, or application site issues

HRT efficacy requires consistent delivery — for transdermal regimens in particular, missing a patch change by 24 or more hours produces a measurable drop in circulating estradiol. Weekly compliance review identifies whether symptom fluctuations are related to dosing consistency before attributing them to dose inadequacy and escalating unnecessarily.

#45

Flag any new symptoms or significant changes from your established perimenopause pattern for clinical review

New symptoms appearing during an established perimenopause presentation — new chest pain, new joint swelling, new neurological symptoms, or new irregular bleeding after a stable pattern — require clinical evaluation rather than perimenopause attribution by default. The weekly review is the structured moment to distinguish evolving perimenopause from a new and unrelated clinical development.

#46

📖 Four Years, Four Specialists, One Missing Conversation

At 44, Catherine's GP diagnosed her with generalized anxiety disorder. At 45, a rheumatologist evaluated her for fibromyalgia. At 46, a sleep clinic attributed her insomnia to psychophysiological conditioning. At 47, a cardiologist cleared her palpitations as benign. Not one of those assessments was wrong — but not one connected the dots to the hormonal transition driving all four presentations simultaneously. A women's health nurse practitioner, reviewing a symptom timeline Catherine had kept for eight weeks, recognized the pattern as perimenopause in under twenty minutes. The subsequent HRT reduced her anxiety episode frequency by roughly two-thirds and restored enough sleep continuity that she no longer needed the behavioral protocol from the sleep clinic. Her four-year diagnostic journey is not a failure story. It is the predictable result of presenting separate symptoms to specialists who were never given the full picture. This tracker is the full picture.

🔍 GP, Gynecologist, or Menopause Specialist — Who Should You See?

Training in menopause medicine varies significantly across specialties — and within them. The right clinician for your situation depends on the complexity of your presentation, not on a default referral pathway.

General Practitioner

A reasonable entry point for initial evaluation and lab work. Many GPs can initiate a standard first-line HRT regimen confidently. Best when your symptom profile is primarily vasomotor and your medical history is uncomplicated.

Gynecologist

Strong choice when cycle abnormalities, genitourinary symptoms, or screening coordination are central concerns. Menopause training varies widely — a gynecologist is not automatically a menopause specialist. Ask specifically about their menopause medicine experience before the appointment.

NAMS-Certified Practitioner

Recommended when symptoms are multi-system, when first-line treatment has produced no response after 12 weeks, or when your personal or family history complicates the standard regimen. Find a certified practitioner at menopause.org — worth traveling for if none is locally available.

🧮 Reading Your MRS Score — What the Numbers Mean in Practice

The Menopause Rating Scale produces a total score from 0–44 across three subscales: somatic (0–16), psychological (0–16), and urogenital (0–12). Your clinician needs the subscale breakdown, not just the total. A score of 22 with 18 points in the psychological subscale and 4 in the urogenital subscale is a completely different treatment conversation from the reverse.

Total Score Benchmarks

0–8 Minimal symptom burden

9–16 Mild — monitoring appropriate

17–24 Moderate — treatment discussion warranted

25+ Severe — active treatment indicated

What Subscale Patterns Suggest

A dominant psychological subscale with low somatic scores often indicates a presentation that responds as well or better to systemic HRT as to SSRIs — a distinction with significant treatment implications. A dominant urogenital subscale with low somatic scores may be fully manageable with local vaginal therapy rather than systemic HRT, which matters greatly for women with contraindications to systemic estrogen.

⚠️ The Timing Window: Why Delaying the HRT Conversation Has a Cost

The "window of opportunity" hypothesis — supported by multiple observational studies and reanalyses of WHI data — holds that HRT initiated within 10 years of the final menstrual period, or before age 60, carries a cardiovascular risk-benefit profile that differs meaningfully from HRT started a decade or more into postmenopause. A woman beginning treatment at 49 is in a fundamentally different clinical position than one beginning at 67, even if their symptom severity is identical.

This is not an argument for beginning HRT without proper evaluation. It is an argument against deferring that evaluation indefinitely — against assuming that because symptoms are currently tolerable, the decision can wait another year or two. The window closes. This tracker builds the documented symptom record that makes an informed, timely decision possible rather than one made reactively after years of suboptimal management.

🚨 Symptoms That Are Not Perimenopause — Seek Urgent or Emergency Care

Perimenopause produces a broad and overlapping symptom picture — but it does not explain everything. The following warrant same-day or emergency evaluation regardless of perimenopausal context, and should not be attributed to hormonal transition without urgent assessment:

⚡ Sudden severe headache unlike any previous headache — seek emergency care immediately.
⚡ Facial drooping, sudden arm weakness, or slurred speech — call emergency services. Women's stroke presentations are frequently atypical.
⚡ Chest pressure or pain radiating to the jaw or left arm — call emergency services. Myocardial infarction in women often presents without classic crushing chest pain.
⚡ Sudden unexplained vision change in one eye — urgent ophthalmology or emergency evaluation.
⚡ Unilateral leg swelling with calf tenderness — urgent DVT evaluation, particularly if you are currently taking oral estrogen.
⚡ Unexplained weight loss exceeding 10 lbs over 6–8 weeks — a dedicated workup is warranted. Do not attribute to perimenopause-related metabolic changes without investigation.

✅ What a Genuine Treatment Response Looks Like

Many women discontinue effective HRT prematurely because they expect complete symptom elimination rather than meaningful reduction. Clinical evidence consistently shows that adequate HRT produces a 75–90% reduction in vasomotor symptom frequency — not resolution to zero. A treatment response worth continuing looks like: hot flashes reduced from 10–12 per day to 2–3, sleep consolidated enough for functional daytime performance, mood stabilization without elimination of all emotional reactivity, and musculoskeletal stiffness that is manageable rather than limiting. If your 12-week MRS has not dropped by at least 30–40% from baseline on a stable regimen, that is a dose or delivery optimization conversation — not evidence that HRT does not work for you personally.

For women who cannot or prefer not to use HRT, the evidence base for non-hormonal management has grown significantly in recent years. Cognitive behavioral therapy adapted for menopausal hot flashes (CBT-MHT) carries Level 1 evidence for vasomotor symptom reduction. The neurokinin B receptor antagonist fezolinetant is a non-hormonal prescription option approved specifically for moderate-to-severe hot flashes. SSRIs and SNRIs — particularly venlafaxine and paroxetine — have evidence for vasomotor symptom reduction at doses below those used for depression. None of these are inferior fallback options: they are targeted treatments for specific presentations, and a menopause specialist can match you to the right approach.

Master This Checklist Quickly

Every important button and option for this pre-made checklist, shown in a glance-friendly format.

Start Here

1
Click any item row to mark it complete.
2
Use the note row under each item for quick notes.
3
Use the tool row for undo, redo, reset, and check all.
4
Use Save Progress when you want to continue later.

Checklist Row Tools

UndoRedoResetCheck allCollapse/Expand sectionsShow/Hide detailsInline notes

Top Action Buttons

Open all sharing and export options in one menu.

Email DraftContinue on another devicePrint or Save as PDFPlain Text (.txt)Word (.docx)Excel (.xlsx)

Add & Ask

Open one menu for apps and AI guidance.

NotionTodoist CSVChatGPTClaude

Copy and customize

Create a new editable checklist pre-filled with your chosen content.

Save Progress

Adds this checklist to My Checklists and keeps your progress in this browser.

Most Natural Usage

Track over time

Check items -> Add notes where needed -> Save Progress

Send or export

Open Share -> Choose format -> Continue

Make your own version

Copy and customize -> Open create page -> Edit freely